<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>IMPROVED QUALITY OF LIFE WITH EPOETIN BETA: In a study against a placebo, there was evidence that the quality of life scores were significantly improved in patients treated with epoetin beta, whether they exhibited a <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumour</z:e> or a malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The same was noted in children with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> exhibiting severe <z:hpo ids='HP_0002664'>neoplasia</z:hpo> and treated with chemotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>The efficacy and tolerance to treatment were equivalent, whatever the administration regimen </plain></SENT>
<SENT sid="3" pm="."><plain>IN PATIENTS SUFFERING FROM MYELODYSPLASTIC SYNDROMES: A particular entity among malignant <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">blood diseases</z:e>, <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> are at the origin of <z:hpo ids='HP_0001903'>anaemia</z:hpo> against which repeated transfusions and growth factors are proposed with varying results and disadvantages, and against which erythropoietin may be moderately effective (a mean of 25% in non-selected cohorts of patients) </plain></SENT>
<SENT sid="4" pm="."><plain>DEPENDING ON THE PROTOCOLS OF ERYTHROPOIETIN ADMINISTRATION IN CASES OF MYELODYSPLASTIC SYNDROMES: Recombinant human erythropoietin, irrespective of its concentration in myelodysplastic cell culture, does not appear capable of restoring <z:mpath ids='MPATH_458'>normal</z:mpath> erythropoiesis </plain></SENT>
<SENT sid="5" pm="."><plain>The influence of prolonged treatment is not admitted by <z:hpo ids='HP_0000001'>all</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>The effects of the addition of growth factors (notably G-CSF) are obvious but some are controversial because of the costs and the prolonged duration of such treatments </plain></SENT>
</text></document>